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SYNDROME ON TRIHEXYPHENIDYL DISCONTINUATION 
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ABSTRACT 
The neuroleptic malignant syndrome (NMS) commonly occurs on treatment with neuroleptics, 
it is also reported in patients who suddenly stop drugs like levodopa, amitriptyline and imipramine. 
We report a case of NMS, which occured in a patient on lithium, haloperidol and trihexyphenidyl 
(THP) after sudden discontinuation of THP. The cholinergic system, through its effect on the 
dopaminergic system, may play a role in the genesis of NMS. Alternatively , anticholinergic 
withdrawal may produce extrapyramidal symptoms (EPS), and the consequent alteration in food 
and fluid intake may produce electrolyte imbalance which increases the risk for NMS. 
KEY WORDS: Neuroleptic Malignant Syndrome, Trihexyphenidyl discontinuation, Anticholinergic 
withdrawal. 
INTRODUCTION 
Rigidity, hyperthermia, alteration in con-
sciousness and autonomic instability are consid-
ered to be the core features of neuroleptic malig-
nant syndrome (NMS) (Addonizio & Susman, 
1991; Caroff & Mann, 1993). Neuroleptics, espe-
cially high - potency ones or high doses of low -
potency ones, are implicated in the genesis of 
NMS. (Addonizio et al ,1987). However, syn-
dromes identical to NMS have been reported in 
patients not taking neuroleptics (Addonizio & 
Susman, 1991). Recently, there have been many 
case reports of a syndrome identical to NMS, 
developing after withdrawal of dopaminergic 
drugs, especially levodopa, in patients with 
Parkinson's disease. (Gibb&Griffith, 1986, Keyser 
andRodnizky, 1991). 
NMS occurring in psychiatric patients on 
withdrawal of drugs with anticholinergic action 
are only sparsely reported (Merriam, 1987; 
Corrigan & Coutter, 1988). To the best of our 
knowledge there are no reports of patients devel-
oping NMS following primary anticholinergic drug 
withdrawal. We report a case of NMS occurring 
in a patient on sudden stoppage of trihexyphenidyl 
(THP). 
CASE REPORT 
Mr. P, a 55 year old man, was brought to 
our outpatient department in January 1994 with a 
history of irritabillity, increased psychomotor ac-
tivity, grandiosity, reduced need for sleep, 
oversociability and impaired judgement. There 
were past episodes of mania in 1984, 1991,1993, 
and depression in 1986. There was no history of 
NMS, contributory organic illness or substance 
abuse. Physical examination was unremarkable. 
An ICD-10 (World Health Organisation , 1992) 
diagnosis of bipolar affective disorder, currently 
mania with psychotic features, was made. The 
patient was admitted and started on lithium 600 
mg per day and haloperidol 30mg per day. A 
week later, he developed mild extrapyramidal 
symptoms (EPS) and THP 4mg per day was 
added. Over a period of two weeks, his manic 
symptoms remitted and he was discharged in 
early February on haloperidol 20 mg per day, 
lithium 600mg per day and THP 4mg per day. At 
the time of discharge, serum lithium was 0.5 
mEq/L and there was no EPS. He was asked to 
come for follow - up after two weeks. 
The dispensary inadvertently gave the pa-
tient THP for 10 days instead of for 14 days. So, 
from the eleventh day of discharge, he was not 
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taking THP, though he continued to take lithium 
and haloperidol. Within two days, he developed 
difficulty in speaking and swallowing, muscular 
rigidity and mild rise in temperature. He was 
brought to our outpatient department the next 
day. 
On examination, he was mildly dehydrated, 
disoriented to time, though orientation to place 
and person was present. He appeared confused, 
had dysarthria and dysphagia. Rigdity was present 
in all four limbs and temperature was 38° C. His 
blood pressure (BP) was 140 /110 mm Hg. There 
was no evidence of focal neurological deficits, 
psychotic symptoms and mood change. There 
was no nausea, vomiting, diarrhoea, myoclonic 
jerks, hyper -reflexia or seizures. Blood tests re-
vealed creatinine phosphokinase (CPK) value of 
4930 units per litre (u /L) (normal range being 10 
- 80 u / L) and white blood cell (WBC) count of 
19,430 per cubic milli metre. Serum lithium was 
0. 96 m Eq /L. Serum electrolytes, liver function 
tests and renal function tests were within normal 
limits. 
The patient was put on intravenous fluids 
and other supportive measures. Oral bromocriptine 
5mg per day was started. All other drugs were 
stopped. However, over the next few days, his 
condition worsened. His level of consciousness 
decreased, he became stuporous and the rigidity 
increased. There were fluctuations in his BP and 
he was sweating profusely. On the third day after 
admission, he lost consciousness and was trans-
ferred to the neurology intensive care unit. On 
that day, blood tests revealed CPK value of 1725 
u / L. WBC count of 15,340 /mm and serum 
lithium as 0. 4.mEq/L. Oral bromocriptine was 
increased to 7.5mg per day. He developed sec-
ondary complications of syndrome of inappropri-
ate anti - diuretic hormone secretion and pneumo-
nia. However, his NMS symptoms improved over 
a period of three weeks and CPK value returned 
to normal limits. 
Two weeks after his admission in the in-
tensive care unit, he started developing hypomanic 
symptoms and so was transferred back to the 
psychiatry ward. The dose of bromocriptine was 
reduced to 2.5 mg per day and was stopped a 
week prior to discharge. Oral lorazepam 3mg per 
day was started to control the hypomania. He 
was discharged by mid-March 1994 . At the time 
of discharge he had no active symptoms of 
NMS. He had mild cognitive deficits character-
ised by mild recent memory and new learning 
impairment. Hypomanic symptoms were in parital 
remission. 
DISCUSSION 
Based on rigidity, alteration in conscious-
ness, increased temperature, raised CPK value 
and autonomic changes, a diagnosis of NMS can 
be made in our patient. The aetiology and 
pathopysisology of NMS is not clearly known 
(Addonizio & Susman, 1991 ; Caroff & Mann, 
1993). The use of high potency neuroleptics, 
concurrent use of lithium, diagnosis of mania 
and possible electolyte imbalance in our patient 
are all known risk factors for the development of 
NMS (Addonizio & Susman, 1991). For a period 
of 10 days after his intial discharge, our patient 
was maintaining the improvement. The symp-
toms of NMS were abrupt in onset and were 
temporally related to the stoppage of 
trihexyphenidyl. It is possible that sudden with-
drawal of anticholinergics might have precipitat-
ed the development of NMS in our patient. Also, 
there are earlier reports of NMS occuring in 
patients on withdrawal of drugs with 
anticholinergic properties like thioridazine, 
amitriptyline, imipramine (Merriam, 1987; 
Corrigan & Coutter, 1988). This supports our 
suggestion that NMS in our patient might have 
occured due to the sudden stoppage of THP. 
There are numerous reports of patients 
developing neurotoxicity on lithium and 
neuroleptic combination ( Prakash et al, 1982). 
More recently , there is increasing attention on 
the enhanced risk of development of NMS on 
this combination (Addonizio et al, 1986; Keck et 
al, 1987). NMS often occurs on this combination 
of drugs when serum lithium is within therapeu-
tic range (Addonizio & Susman, 1991). Though 
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neurotoxicity has been reported in patients taking 
lithium alone, even when the serum lithium is 
within therapeutic range (West and Meltzer 1979), 
it usually occurs when serum lithium is in the 
toxic range (Goodwin & Jamison 1990). Though 
relapse of NMS has been reported on lithium re -
challenge (Susman & Addonizio, 1987), 
occurence of NMS for the first time on lithium 
alone when serum lithium is in the therapeutic 
range has not been reported. Since the serum 
lithium was within normal limits at the time of the 
patient's original discharge and re-admission with 
NMS symptoms, and the absence of other asso-
ciated symptoms of lithium toxicity , it is unlikely 
that our patient had a primary lithium toxicity. 
However, the concurrent usage of lithium might 
have most likely increased the risk of developing 
NMS in our patient. 
Cholinergic receptor supersensitivity can 
occur as a result of treatment with anticholinergics 
(Disalver et al, 1987). Sudden withdrawal of 
anticholinergics can produce a hypercholinergic 
state, which has been postulated to evoke a 
hypodopaminergic state increasing the risk of 
development of NMS (Corrigan & Coutter, 1988). 
Alternatively anticholinergic withdrawal may pro-
duce EPS which can result in dysphagia. This can 
produce an electrolyte imbalance and metabolic 
changes which have been implicated in increasing 
the risk for the genesis of NMS (Addonizio & 
Susman, 1991). 
Most hypotheses regarding the 
pathophysiology of NMS revolve around a 
hypodopaminergic state in the central nervous 
system, especially in the striatum and hypothalamus 
(Addonizio, 1987). The occurrence of a NMS -
like state in patients with Parkinson's disease sud-
denly, when dopaminergic agonists like levodopa 
and bromocroptine were stopped, has also been 
put forward to support the above hypotheses 
(Gibb & Griffith ,1986; Keyzer & Rodnizky, 
1991). However, a careful analysis of the above 
literature reveals that most of these patients were 
on a variety of other drugs like anticholinergics, 
anthihistaminics and amantadine, which were also 
withdrawn. Hence it can be argued that the NMS 
in these patients may not be due to levodopa 
withdrawal alone. 
Current models of NMS based on the 
hypodopaminergic state alone may be too sim-
plistic and may not be able to explain the complex 
physiological changes and pharmacological re-
sponses in these patients. The role of other po-
tential neurochemicals like acetylcholine, 
norepinephrine, gammaaminobutyric acid, 
serotonin and glutamic acid needs further explo-
ration. It might be worthwhile to be on the 
lookout for NMS when anticholinergics are with-
drawn, especially when patients have other risk 
factors for the development of NMS. 
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